SCHEMBL2861580

SCHEMBL2861580

CC1(C)OC(=O)N2CCN(C(=O)OCc3ccccc3)CC21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
NPSR1 Q6W5P4 4/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
ADRB2 P07550 1/20 0.43
APLNR P35414 1/20 0.43
GLP1R P43220 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867943 0.86 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL2856681 0.86 NPSR1 (0.67) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL778102 0.76 MEN1 (0.51) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL28810466 0.75 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL3068185 0.75 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL2679927 0.74 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL18075928 0.74 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL23683797 0.74 MEN1 (0.51) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL27308965 0.73 MEN1 (0.46) SMN1; SMN2NPC1RAB9ANPSR1MEN1
SCHEMBL27308968 0.73 MEN1 (0.46) SMN1; SMN2NPC1RAB9ANPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 SMN1; SMN2 4533/4885NPC1 1081/4885RAB9A 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.